2024年11月5日,生命科学公司Cytek Biosciences(CTKB)盘中股价大涨6.35%,报收于5.58美元。这主要得益于公司当晚公布的2024年第三季度业绩超出市场预期。
CTKB在上周五晚间公布的最新季报显示,第三季度该公司实现营收5150万美元,同比增长7.3%;每股收益1美分,超出分析师此前的平均预期亏损1美分。正是由于这份外延预期的业绩表现,该公司当日股价应声大涨。
公司CEO温恩斯曼表示,第三季度业绩主要得益于细胞分析系统Aurora和Northern Lights的销售持续走强。尽管面临通胀和汇率波动等挑战,公司的生物学工具从事业发展到生产据点搬迁都取得了进展,为下一步发展奠定基础。随着细胞分析行业需求的不断增长,CTKB将抓住机遇进一步扩大市场份额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.